Everest Medicines Ltd Financials

Market Capitalization HK$21.78 Billion as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE	658.75
Forward PE	-55.96
Price to Sales TTM	HK$30.82
Price to Book MRQ	HK$5.35
Enterprise to Revenue	27.09
Enterprise to EBITDA	-28.58

Financial Reports as of Jun. 30, 2020

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2020-06-30
Profit Margin	-147.36%
Operating Margin	-26.77%
Return on Assets TTM	-9.09%
Return on Equity TTM	-23.04%

Income Statement

Revenue TTM	HK$773,529,756
Revenue per Share TTM	HK$2.20
Quarterly Revenue Growth	246.20%
Gross Profit TTM	HK$578,924,097
EBITDA	HK$-733,430,197
Net Income to Common TTM	HK$-1,139,889,048
Diluted EPS TTM	HK$-3.55
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	HK$1,754,980,971
Total Cash per Share MRQ	HK$4.94
Total Debt MRQ	HK$
Total Debt to Equity MRQ	14.13
Current Ratio MRQ	2.54
Book Value per Share MRQ	HK$12.56

Cash Flow

Operating Cash Flow TTM	HK$-743,794,956
Levered Free Cash Flow TTM	HK$-754,836,860

1952 Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	324,347,608
Float Shares	235,787,737
Avg 10 Volume	7,571,509
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.57%
% Held by Institutions	33.61%

Stock Price Summary

Beta	1.60
Fifty Two Week Low	HK$18.18
Fifty Two Week High	HK$69.00
Fifty Two Week Change	72.66%
Day 50 MA	HK$49.30
Day 200 MA	HK$43.24

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date